Purchase this article with an account.
Chieko Shiragami, Yukari Takasago, Rie Osaka, Mamoru Kobayashi, Aoi Ono, Ayana Yamashita, Kazuyuki Hirooka; Clinical features of central serous chorioretinopathy with type 1 choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3133. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the incidence of type 1 choroidal neovascularization (CNV) in central serous chorioretinopathy (CSC) and examine the factors influencing the appearance of CNV.
A review of the medical records of 363 eyes of 324 patients with CSC was conducted. Optical coherence tomography (OCT), and indocyanine green and fluorescein angiography results were available. The patients were divided into group 1 (non-neovascular CSC) and group 2 (neovascular CSC) and a statistical comparison of data-points including age, sex, type of CSC, choroidal vascular hyperpermeability, logMAR best corrected visual acuity (BCVA), subfoveal choroidal thickness (SCT), and systemic hypertension (HT) was performed.
The review identified 219 eyes with chronic CSC and 144 eyes with classic CSC. The mean age was 55.2 ± 12.0 years. Two hundred and forty patients (74.1%) were male. Of the 363 eyes, 58 (15.6%) were in group 2. Mean age, logMAR BCVA, and SCT of group 1/group 2 were 54.8 ± 12.1/57.3 ± 10.9 (P = 0.118), 0.15 ± 0.29/0.28 ± 0.33 (P = 0.014), and 388.0 ± 104.5 µm/377.4 ± 108.9 µm (P = 0.487), respectively. The number of females and eyes with chronic CSC, choroidal vascular hyperpermeability, and HT in group 1/group 2 was 72 (23.6%)/20 (34.5%) (P = 0.099), 171 (56.1%)/48 (82.8%) (P < 0.001), 205 (67.2%)/58 (100%) (P < 0.001), and 91 (29.8%)/24 s (41.4%) (P = 0.092), respectively. Chronic CSC (P = 0.001), female sex (P = 0.075), and logMAR BCVA (P = 0.091) were significantly associated with group 2 on logistic regression analysis.
Chronic CSC is significantly associated with CNV. Female sex, choroidal vascular hyperpermeability, and poor VA are other risk factors that can lead to neovascularization in CSC.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only